bluuebunny/crossref_metadata_2025 huggingface dataset:
Cryptogenic stroke and extrasystolic arrythmia: is there any correlation?
Authors: Germanova O , Germanov A V , Galati G
Published: October 2022

Up to 45% of all ischemic strokes (IS) are cryptogenic.

Purpose

To reveal the possible reasons of cryptogenic IS.

Methods

We analyzed the cases of computer tomography verified IS in patients admitted the hospital during the period of 3 years. All these 268 patients had unidentified source of IS. We analyzed hemostasiograms, lipids levels, performed echocardiography, Doppler ultrasound of brachiocephalic arteries, 24-hours ECG monitoring and common carotid arteries sphygmography (SG).

Results

None of the patients had atrial fibrillation, hemodynamically significant stenoses of brachiocephalic arteries or hematological pathology associated with hypercoagulation. 234 (87.3%) patients had atherosclerotic plaques in carotid area bifurcation (in 36 (13.4%) – intima-media thickness was 1.1 mm, in 74 (27.6%)– stenosis <40%, in 124 (46.3%) had 40–69% stenosis in diameter). The internal carotid stenosis in diameter is calculated by ECST, NASCET and St. Mary's ratio criteria. To detect the type of the plaques we used Gray-Weale–Nicolaides ultrasound classification. In 39 (14.5%) was type I: uniformly echolucent plaque; in 88 (32.8%) type II: predominately echolucent plaque; in 71 (26.5%) type III: predominantly echogenic plaque, none had type IV: uniformly echogenic plaque or type V: heavy calcification. In 24-hours ECG monitoring and SG we revealed that most of the patients – 244 (91.0%) had extrasystolic arrhythmia which ventricular contraction of extrasystole appeared in the early phase of cardiocycle – before the transmitral blood flow peak. In 1st post-extrasystolic wave after such extrasystole we detected the growth of linear blood flow speed in carotid bifurcation (2.5 m/sec) and kinetic arteries parameters of SG (2.6 times).

Conclusion

The appearance of IS is higher in patients with extrasystolic arrhythmia appearing in the cardiocycle before the transmitral blood flow peak. In cryptogenic stroke, the reason of it can be the atherosclerotic plaque defragmentation with further embolism, caused by the additional mechanical trauma of increased hemodynamical and kinetic parameters of pulse wave of the 1st post-extrasystolic contraction.

Funding Acknowledgement

Type of funding sources: None.
Mobitz type I 2nd degree atrioventricular (Wenckebach) block and cardiovascular death using 978,901 12 lead ECGs recordings
Authors: Hendriksen S , Karlsen F M , Philbert B T , Person S , Koeber L , Torp-Pedersen C , Bang C N
Published: October 2022

Background

Mobitz type I 2nd degree atrioventricular (AV) block (Wenckebach) is usually considered benign. Guidelines recommend permanent cardiac pacing for patients with Mobitz type II second degree AV block (Mobitz II), but for patients with Wenckebach, permanent pacing is only indicated if the AV block causes symptoms or if the conductions delay occurs below the bundle of His. However, these guidelines are based on evidence of modest quality and a consensus amongst experts (1).

Purpose

This study aims to investigate if Wenckebach really is benign by comparing the risk of cardiovascular death for patients with Wenckebach to patients with normal ECGs.

Methods

This retrospective cohort study included 978,901 ECGs obtained from general practitioners in Denmark from 01/02/2001 to 31/10/2014. Index date was the day of the ECG recording and the patients were followed until death or end of follow up at December 2019.

The association between Wenckebach and cardiovascular death was analyzed using: 1) multivariate Cox models adjusted for age and comorbidities, 2) cause-specific Cox models and 3) cumulative risk and cause-specific hazard function plots, compared to matched controls. Information about comorbidities, pacemaker, indications, and death was retrieved from Danish nationwide registries.

Results

From the 978,901 ECG recordings, we found 262 patients with Wenckebach, 131 patients with Mobitz II, and 229,056 patients with normal ECGs. In Wenckebach, Mobitz II, and normal ECG the median age was 76, 80, and 50 years, 76%, 63%, and 41% were male, 25%, 16%, and 3% had diabetes, 35%, 30%, and 8% had hypertension, respectively.

During a mean follow-up of 11.2 years, cardiovascular death occurred in a total of 11,301 patients: 77 (29%) patients with Wenckebach, 40 (31%) patients with Mobitz II, and 11,184 (5%) patients with normal ECGs. In a matched cohort 262 Wenckebach patients were matched with 520 controls with normal ECGs. In the multivariate Cox model, Wenckebach was associated with cardiovascular death (HR: 2.14 [95% CI: 1.46–3.13], P<0.001). Furthermore, in multivariate cause-specific Cox analysis with non-cardiovascular death and pacemaker as competing risk, Wenckebach was still associated with cardiovascular death (HR: 2.27 [95% CI: 1.37–3.75], P=0.001).

Furthermore, the results showed that 43% of the Wenckebach patients received pacemaker with a median time to pacemaker from ECG recording being 252 days. The vast majority of the Wenckebach patients who received pacemaker had a higher degree AV block than Wenckebach as indication for the implantation.

Conclusion

Wenckebach on routine ECG was associated with a significant higher hazard rate of cardiovascular death compared to matched controls with normal ECGs.

Funding Acknowledgement

Type of funding sources: Foundation. Main funding source(s): The Danish Heart Association
Incidence of atrial and ventricular arrhythmias in patients with CIEDs and COVID-19
Authors: Margulescu A D , Thomas D E , Kakoudaki M , Cranch H , O'Dea J , Davies G , Phillips A , Green A S , Rees P , Barry J P
Published: October 2022

Background

It remains unclear whether COVID-19 infection is associated with increased arrhythmia burden in patients with cardiac implantable electronic devices (CIEDs).

Methods

We identified 46 patients tested positive for COVID-19 between 01/03/2020 and 31/05/2021 in our cohort of 1209 patients with CIED (3.8%). Data on arrhythmia burden during a 9 week period (a 4 week “pre-infection” period: P1, the week before the positive Covid-19 test: P2, and the 4 weeks afterwards: P3) was accessible in 35 patients.

Results

83% of patients were not hospitalised. Five patients (14.3%) (all non-hospitalised) had high rate atrial (HRA) events, 4 of which exclusively during P1 and/or P2. Thirty-two non-sustained VT (NSVT) episodes were recorded in 8 patients, one degenerating in VF requiring ICD shock (occurring in P2). One patient had frequent NSVT each week. After exclusion of this outlier, a numerical 4-fold increase in weekly NSVT episodes was observed between P1 and P3 (Patients with NSVT: 0.07±0.12 vs. 0.29±0.17 episodes/week, p=0.057; entire cohort: 0.015±0.060 vs. 0.059±0.138 episodes/week, p=0.16) (Figure 1). In P3, hospitalised patients had a trend towards higher NSVT burden vs. non-hospitalised patients (2/6 (33.3%) vs. 4/29 (13.8%), p=0.27) which was not apparent before the positive Covid-19 test.

Conclusion

Our single-centre experience suggests that COVID-19 infection may result in an increase in VA but not atrial arrhythmia burden in patients with CIED.

Funding Acknowledgement

Type of funding sources: None.
Incidence of atrial fibrillation/flutter, one-year re-admission rates, and practice patterns among patients <65 years of age: a Danish nationwide study
Authors: Schak Nielsen L , Kofoed Petersen J , Emborg Vinding N , Andersson C , Weeke P E , Lund Kristensen S , Gundlund A , Schou M , Koeber L , Fosboel E L , Oestergaard L
Published: October 2022

Background/Introduction

The general atrial fibrillation/flutter (AF) population is well explored and described, but there is sparse data on temporal changes in the incidence, AF-readmission rates, and practice patterns in patients with AF under 65 years of age from unselected cohorts.

Purpose

To investigate temporal changes, AF readmission rates, and practice patterns in patients under 65 years of age with first-time AF diagnosed between 2000–2018.

Methods

Using Danish nationwide registries, we identified patients >18 years and <65 years with a first-time AF-diagnosis from 2000–2018. The cohort was categorized according to calendar periods; 2000–2002, 2003–2006, 2007–2010, 2011–2014 and 2015–2018. Incidence rate (IR) of AF per 100,000 person years (PY), AF-readmission, and practice patterns of medical treatment, electrical cardioversion, and catheter ablation was investigated in the first year following AF-diagnosis.

Results

In this study 60,917 patients were included; 8,150 patients (13.4%) in 2000–2002, 11,898 (19.5%) in 2003–2006, 13,560 (22.3%) in 2007–2010, 14,167 (23.3%) in 2011–2014 and 13,142 (21.6%) in 2015–2018. No major differences were seen in patient characteristics according to calendar period. A stepwise increase, as seen in the Table, in the crude IR of AF per 100,000 PY was observed across calendar periods, except for 2015–2018 (Crude IR [95% CI]: 2000–2002: 78.7 [77.0; 80.4], 2003–2006: 86.3 [84.7; 87.8], 2007–2010: 97.9 [96.3; 99.6], 2011–2014: 102.3 [100.7; 104.0], 2015–2018: 93.6 [92.0; 95.2], while no difference in AF readmission was identified (AF-readmissions: 2000–2002: 32.7%, 2003–2006: 31.1%, 2007–2010: 32.2%, 2011–2014: 32.1% and 2015–2018: 31.7%), as seen in the Figure, right panel. In the first year following AF-diagnosis, the cumulative incidence of catheter ablation increased stepwise from 1.2% in 2000–2002 to 7.6% in 2015–2018 and electrical cardioversion from 2.0% in 2000–2002 to 8.7% in 2015–2018 (Figure, left panel). Treatment with oral anticoagulant therapy (OAC) increased from 28.5% in 2000–2002 to 47.8% in 2015–2018, while there was no change in treatment with rhythm or rate medication therapy.

Conclusion

From 2000–2018, we found an increase in the incidence of atrial fibrillation/flutter (AF) in patients <65 years from 78.7/100,000 person years (PY) to 93.6/100,000 PY and an increase in the use of catheter ablation, electrical cardioversion and OAC in the first year following first-time AF-diagnosis. AF readmission rates were stable over calendar periods.

Funding Acknowledgement

Type of funding sources: None.
Electrocardiographic profile of asymptomatic adolescents by the TELE ECG system in Brazil: analysis of 11058 patients
Authors: Nogueira M F , Andalaft R , Hinkelmann Berbert G , Valdigem B , Pinto V B C , Moretti M P , Felicioni S P , Fernandes R C , Franca F F A C , Freitas R V , Feres F
Published: October 2022

Introduction

The search for markers that can serve as screening methods for young practitioners of physical activity has always raised an intense discussion between pediatricians and cardiologists. Thus, the ideal investigation algorithm should identify patients at high risk also among asymptomatic patients and be of low cost to society. This would only be possible by including a low cost diagnostic method and largely accessible. In this context, telemedicine systems and in particular tele-electrocardiogram (tele-EKG) systems have low cost and agility and can collaborate to solve this problem.

Purpose

To analyze the electrocardiographic pattern in asymptomatic patients aged between 10 and 20 years old who underwent EKG by the tele-EKG system between 2007 and 2014

Methods

All EKG valid results from asymptomatic patients aged between 10 and 20 years old from 2007 and 2014 sent to the tele-EKG system of a large tertiary hospital were analysed aiming to determine the prevalence of abnormal findings.

Results

Of the 797,115 exams on the analysed period 25,326 were from patients aged between 10 and 20 years old and 11,058 (55% male) of them were asymptomatic. Regarding disorders of rhythm, ventricular arrhythmias were found in 0.54% and atrial premature beats in 0.47% of the exams. There were 5 episodes of supraventricular tachycardia (0.04%) and one episode of atrial fibrillation. Atrioventricular blocks were: first degree (0.71%) and second degree (0.03%). There was 1 case of 2:1 AV Block and 1 case of advanced AV block. Short PR interval was observed in 0.76% of the exams, with 15 of them showing ventricular pre-excitation (0.13%). Regarding morphological changes in EKG pattern, right bundle branch disorders were present in 7.5% of the patients and left bundle branch in 0.04%. Right bundle branch block occurred in 0.63% and left bundle branch block in only 1 case. Repolarization changes occurred in 1.8% of patients. We found left ventricular overload in 0.25% and right ventricular overload in 0.14% of cases. Only 5 patients had typical EKG of septal hypertrophy (0.045%). There were 1751 diagnostics overall, representing 15.8% of the sample. The most prevalent was right bundle branch abnormalities, followed by repolarization abnormalities (graphic below).

Conclusion

EKG screening in asymptomatic adolescents is a low cost and feasible method to identify individuals with electrical alterations and who require detailed clinical evaluation. This also may contribute to reduce risk of sudden events during sports activities.

Funding Acknowledgement

Type of funding sources: None.
Impaired heart rate variability one and six months post acute COVID-19
Authors: Lampsas S , Oikonomou E , Souvaliotis N , Goliopoulou A , Papamikroulis G A , Anastasiou A , Theofilis P , Zakynthinos G , Gialamas I , Pantelidis P , Gounaridi M A , Tsatsaragkou A , Siasos G , Tousoulis D , Vavuranakis M
Published: October 2022

Background

Long COVID-19 syndrome is an increasingly recognized problem. Post-infectious cardiac autonomic dysfunction is commonly reported. This study aims to evaluate autonomic dysfunction by means of Heart rate variability (HRV) on post-COVID-19 patients.

Methods

Hospitalized patients for COVID-19 (either at the medical ward or Intensive Care Unit (ICU)) were followed up at 1 and 6 months after hospital discharge. Medical history and clinical information were collected. HRV was assessed by 24-hour ambulatory electrocardiography Holter, with the measure of the standard deviation of normal RR intervals in 24 h, ms (SDNN). The comparison was conducted with age and sex-matched non-COVID-19 controls.

Results

Thirty-four patients hospitalized with COVID-19 (20.6% admitted in ICU) were examined 1-month and 6-months post-hospital discharge. SDNN was significantly (p<0.001) reduced in the COVID-19 group (111±23 ms) compared to the control subjects (152±24 ms) 1-month after discharge. Subgroup analysis between COVID-19 group revealed that ICU subjects presented significantly (p<0.001) reduced SDNN compared to the medical ward, respectively (83±20 ms vs. 118±17 ms). At 6-months, an improvement was noted at SDNN 24h (6-month: 133±24 vs. control: 151±24 ms, p=0.004; 1-month: 111±23 ms vs. 6-month: 133±24 ms, p<0.001). Also at 6-months, ICU subjects noted significantly (p=0.003) reduced SDNN 24h compared to medical ward subjects (107±17 ms vs. 140±20 ms). On the 6-months follow-up, 32% of the subjects had “long-COVID-19” symptoms. Subjects with long COVID-19 symptoms had low SDNN values (“long-COVID-19”: 112±17 ms vs. non-“long-COVID-19”: 142±20 ms, p=0.001)

Conclusion

Patients hospitalized for COVID-19 have reduced SDNN, at one month post-hospital discharge which is improved at the six months follow-up. These findings emphasize the increased sympathetic drive activity in the post-acute COVID-19 phase and imply a link between autonomic dysfunction and long COVID-19.

Funding Acknowledgement

Type of funding sources: None.
Premature ventricular complexes are not independently associated with concurrent paroxysmal atrial fibrillation on mobile cardiac telemetry
Authors: Maneheim A , Juhlin T , Dziubinski M , Slusarczyk M , Grotek A , Engstrom G , Johnson L S B
Published: October 2022

Background

Premature ventricular complexes (PVCs) on 24hECG predict incident atrial fibrillation in long-term prospective studies, but whether PVCs detected on ambulatory monitoring indicate a risk of concurrent paroxysmal atrial fibrillation is unknown.

Objectives

To determine whether PVCs predict paroxysmal atrial fibrillation on ≤30-day ambulatory mobile cardiac telemetry (MCT).

Methods

US patients aged 17–100 years with 2–30 full days of ambulatory full-disclosure ECG using a mobile cardiac telemetry device, without atrial fibrillation on their first day of recording, were included. The association between PVC frequency on recording day 1 and and the outcome of atrial fibrillation ≥30 seconds during subsequent recording days was analysed using age and sex adjusted logistic regression models and restricted cubic splines, with additional adjustment for premature atrial contractions (PACs).

Results

The study population included 18,220 patients with a mean age 64 years; 58% were female. Median monitoring duration was 19 days (interquartile range 9–29). PVC and PAC frequency were moderatly correlated, Spearmans rho 0.359, p<0.0001. Using logistic regression analyses adjusted for age, sex and recording duration, PVCs were associated with atrial fibrillation detection (Figure 1a), but in models additionally adjusted for PAC frequency there was no remaining effect of PVC frequency on atrial fibrillation risk (Figure 1b).

Conclusions

A finding of PVCs, in the absence of PACs, on 24hECGs does not imply increased risk of concurrent paroxysmal atrial fibrillation detected on ≤30 day MCT.

Funding Acknowledgement

Type of funding sources: Foundation. Main funding source(s): Hjärt-Lungfonden, Swedish Society for Medical Research
Recurrence of atrial fibrillation following pulmonary vein isolation: impact of body mass index on one- and three-year outcomes
Authors: Milstein N , Saberito M , Bhatt A , Habibi M , Sichrovsky T , Preminger M , Shaw R , Mittal S , Musat D
Published: October 2022

Background

Cryoballoon (CB) pulmonary vein isolation (PVI) is an accepted method for ablation in patients with paroxysmal and persistent atrial fibrillation (PAF, PeAF). However, there are a paucity of data about the impact of body mass index (BMI) on one-year and longer-term outcomes following ablation.

Objective

To objectively understand the impact of BMI on outcomes following CB PVI.

Methods

We enrolled consecutive AF patients undergoing CB PVI; all patients had an implantable loop recorder (ILR), which transmitted data wirelessly daily. We assessed AF recurrences after excluding an initial 3-month post-ablation blanking period.

Results

The cohort included 222 pts (66±9 years; 143 [64%] male; 120 [54%] PAF; CHA2DS2-VASc 2.6±1.6). The mean BMI was 30±5. Patients were followed for 763±347 days, during which time 50% and 68% had recurrent AF 1- and 3-years post ablation. We divided the cohort based on the mean BMI into 2 groups: BMI <30 and BMI >30. Heavier patients were younger and more likely to have PeAF. Over 1-year of follow-up, patients with a BMI <30 had similar likelihood of being free of AF to patients with a BMI >30 (46% vs, 56%, p=0.0.097, Figure 1, left). However, as patients were followed for 3-years, freedom from AF was significantly higher in patients with a BMI <30 (59% vs. 81% in BMI >30, p=0.002, Figure 1, right).

Conclusions

Our data show that although patients had similar outcomes 1-year post-ablation, during longer-term follow-up patients with a BMI >30 had a much worse outcome. Our study uniquely offers objective (using an ILR) assessment of the impact of BMI on long-term outcomes following CB PVI (homogenous ablation strategy). These data highlight the need to identify strategies to improve outcomes in obese patients.

Funding Acknowledgement

Type of funding sources: None.
Atrial fibrillation detection in ambulatory patients using a smart ring powered by deep learning analysis of continuous photoplethysmography monitoring
Authors: Kwon S , Choi E K , Lee S R , Ahn H J , Lee B , Oh S , Lip G Y H
Published: October 2022

Background

Atrial fibrillation (AF) detection could be effective with photoplethysmography (PPG) signal monitoring by a wearable device.

Purpose

We aimed to validate the performance of AF detection among ambulatory patients who underwent electrical cardioversion for AF using a smart ring capable of continuous PPG monitoring and deep learning analysis.

Methods

In this prospective single-arm study, participants who underwent successful electrical cardioversion for AF were enrolled. The participants equipped a smart ring (CardioTracker, Sky Labs Inc., Seongnam, Republic of Korea) after the electrical cardioversion. The smart ring then continuously monitored PPG over 14 days to detect AF recurrence. The smart ring alarmed AF episodes based on deep learning analysis of PPG. The participants were asked to measure at least three daily ECGs using the smart ring to validate AF recurrence detected by PPG. All ECG snapshots were recorded along with lead I and saved with simultaneous PPG. ECG data were examined by the three cardiologists independently (SK, SRL, and EKC). The monitoring time, analyzable proportions of monitored signals, detection rates of AF episodes, and the diagnostic performance of PPG-based deep learning were evaluated. At the end of the monitoring, a survey on the use of the smart ring was performed.

Results

A total of 35 participants (mean age 58.9 years, male 74.3%) were enrolled. Figure 1 illustrates an example of PPG monitoring and PPG-ECG snapshots by the smart ring. The study participation period was a median of 14 days and the wearing time of the smart ring was a median of 9.2 days (IQR 7.1–11.5 days). Signal artifacts during daily activity decreased the analyzable proportions of monitored PPG by 68.5%. Irregular pulse episodes were detected by the smart ring in 29 (82.9%) participants after a median of 1 day from the cardioversion (Figure 2). A total of 2532 PPG-ECG snapshots were acquired and 1623 (64.1%) were interpretable by both the cardiologists (using ECG) and the deep learning analysis (using PPG). Comparing PPG by simultaneous ECG, the performance of AF detection by the smart ring was 98.7% for sensitivity, 97.8% for specificity, 2.2% for false positives, and 1.3% for false negatives (Figure 2). After using the smart ring, 76.9% of the participants responded that they had no discomfort in using the smart ring in daily activity and another 76.9% responded that it was helpful to monitor their disease.

Conclusion

Despite the signal artifacts during daily activity, AF detection with PPG monitoring by a smart ring could be effective for AF screening among ambulatory patients.

Funding Acknowledgement

Type of funding sources: Private company. Main funding source(s): This work was supported by Sky Labs Inc, Seongnam, Republic of Korea, and by the grant No. 0320202040 from the Seoul National University Hospital Research Fund.
Syncopal patients without prodromes exhibit a diverse pattern of adenosine release during head-up tilt test
Authors: Fragakis N , Antoniadis A , Sotiriadou M , Virgiliou C , Ballauri I , Gika H , Boulmpou A , Triantafyllou K , Vergopoulos S , Bakogiannis C , Papadopoulos C , Tzikas S , Karamitsos T , Vassilikos V
Published: October 2022

Background/Introduction

In a significant proportion of patients with neurally-mediated syncope (NMS), the mechanism of syncope remains largely undetermined. Adenosine has been proposed as a central humoral factor in various forms of NMS: high Adenosine Plasma Levels (ADP) are encountered in patients with vasovagal syncope (VVS), low ADP in non-prodromes syncope (NPS), while ADP in patients with situational syncope SS are less well determined.

Purpose

We sought to assess ADP in patients with different clinical forms of syncope, with an emphasis on the presence or absence of prodromal symptoms, as well as the relation between ADP and the outcomes of Head-Up Tilt Table Test (HUTT) and Adenosine test (ADT).

Methods

Patients with different clinical types of NMS (n=124), i.e., VVS, NPS, or SS, were investigated using a standard protocol including HUTT and ADT. During HUTT, ADP was measured in the supine position, at table tilting, and in syncope.

Results

Baseline ADP did not differ among groups. ADP at syncope were higher in NPS compared to VVS (1.55±1.29 vs 0.16±0.05 μM, p=0.03) and SS (0.15±0.05 μM, p=0.02). In NPS, ADP increased from the supine position to the time of syncope (0.47±0.25 to 1.55±1.29 μM, p=0.04). In VVS, ADP increased only from the supine to the tilt position (0.23±0.04 to 0.35±0.10 μMu, p=0.02), while in SS ADP did not change in any stage of HUTT. SS was associated with cardioinhibitory HUTT (OR 3.40, 95% CI 1.05 to 9.56, p=0.04) and positive ADT (OR 4.22, 95% CI 1.47 to 11.46, p=0.012).

Conclusion(s)

A distinct pattern of ADP increase is noted during HUTT in NPS, suggesting that an excessive increase of ADP may play the key role in triggering this type of clinical presentation of syncope independently of the baseline ADP. Cardioinhibition prevails in patients with SS without clear adenosine involvement. Such observations contribute to an enhanced understanding of the pathophysiology of different clinical forms of syncope which may offer the possibility to tailor the management approach appropriately.

Funding Acknowledgement

Type of funding sources: None.
Risk stratification of sudden cardiac death in subjects with asymptomatic ventricular preexcitation: diagnostic value of non-invasive and invasive methods
Authors: Chilabert D , Diangelo S , Lanzotti M , Antonietta C , Menoyo M , Pilon L , Viale S , Bagnera F
Published: October 2022

Introduction

In subjects with asymptomatic ventricular preexcitation (AVP) guidelines recommend follow-up by non-invasive methods. However, in some patients accessory pathways (APs) show high-risk invasive parameters and risk of sudden death.

Objectives

To assess the association between the non-invasive and invasive risk stratification (NIRS and IRS) in AVP patients in our center.

Material and methods

Retrospective and observational study in 58 patients with AVP, underwent NIRS and IRS. Association between NIRS (electrocardiogram, holter and ergometry testing) and IRS variables (AERP ≤250 msec, SPERRI ≤250 msec, atrioventricular reentrant tachycardia or AF, multiple APs) from the electrophysiological study (EPS), and sensitivity and specificity of NIRS to predict a high-risk EPS were determined.

Results

Of patients with high-risk EPS (n=41), 55% had a previously low-risk NIRS (n=11) while 78% (n=30) had a high-risk NIRS (p=0.05). A low-risk NIRS had a sensitivity (S) 27% and specificity (E) 47% to predict a high-risk EPS.

Conclusions

In our population, 1 of every 2 patients with low-risk NIRS presented a high-risk IRS. The NIRS methods present low S and E for risk stratification in AVP patients.

Funding Acknowledgement

Type of funding sources: None.
The veins of the left ventricular summit in patients undergoing cardiac resynchronization therapy
Authors: Zehan I G , Andrei M G , Coseriu G , Eotvos C A , Lazar R D , Jelnean M , Tentea C P , Porca A D , Negru A , Burde A , Moldovan M , Chiorescu R , Pop S , Heist E K , Blendea D
Published: October 2022

Introduction

While the coronary sinus and its left ventricular branches have been extensively described, the veins of the left ventricle summit (LVS) have been much less studied. The emergence of new ablation techniques for ventricular tachycardias, which make use of the LVS veins, has generated a renewed interest in the anatomy of these venous conduits.

Purpose

The aim of the study was to describe in detail the anatomy of the LVS veins using rotational venous angiography.

Material and methods

All patients (N=106, age 68±12 years, 72 men) underwent coronary venous angiography during the cardiac resynchronization implant procedures.

Results

The LVS veins identified were the great cardiac vein (GCV), the anterior interventricular vein (AIV) and the mitro-aortic LVS vein (MALVSV). The MALSV emerged from the GCV between 12 and 2 o'clock on the mitral ring, coursed inside the left atrioventricular groove, towards the aorto-mitral continuity (AMC), where it turned towards the ventricular septum and coursed parallel to the AIV, tapered down and ended at midventricular level. Most of the course of this vein was in the region of the LVS. The diameter of the venous conduit at the GCV-AIV junction was 4.9±1.0 mm. The MALVSV was present in 76 patients (72%; Figure 1). The MALVSV diameter was 2.4±0.6mm at the ostium (Figure 2) and 1.8±2.0 mm at the AMC. The takeoff angle was 134±27°. The total length of the vein was 34±16 mm, of which 23±14mm were inside the AV groove and 11±9mm, were along the ventricular septum. The length of the MALSV segment embedded in the left AV groove as well as the total length of MALSV correlated significantly with the left atrial diameter (r=0.44; P=0.040 and r=0.45; p=0.016 respectively) as well as with the right ventricular systolic pressure (r=0.50; p=0.028 and r=0.57; P=0.030 respectively).

Conclusions

This study brings new insights into the angiographic anatomy of the LVS veins. Detailed knowledge of these venous tributaries could help with the development of new strategies for ablation of LVS tachycardias.

Funding Acknowledgement

Type of funding sources: None.
Prevalence of modifiable risk factors and related poor cardiovascular outcomes following atrial fibrillation ablation
Authors: Stout K , Adomako R , Almerstani M , Shin D , Tandon H , Schleifer J , Payne J , Easley A , Khan F , Windle J , Tsai S , Anderson D , Naksuk N
Published: October 2022

Background

Atrial fibrillation (AF) has become a global epidemic. Early catheter ablation and therapies modifying risk factors (RF) have been shown to improve outcomes of AF ablation. However, the time invested in pursuing risk factor modification may delay ablation, which could negate the procedural benefit.

Purpose

This study sought to investigate the prevalence and impact of potentially modifiable RF among AF patients undergoing catheter ablation in clinical practice.

Methods

This retrospective study included 724 consecutive patients undergoing AF ablation at a tertiary care center from 2012–2019. Pre-specified modifiable risks were examined, including the time from AF diagnosis to ablation, fluctuation/increase in BMI >5% prior to ablation, mean systolic/diastolic blood pressure >125/80 mmHg, obstructive sleep apnea with CPAP noncompliance, hyperlipidemia without statin therapy, tobacco use, excessive alcohol use, and diabetes mellitus with hemoglobin A1c (HbA1c) >6.5%. The primary outcome was a composite of recurrent atrial arrhythmias, cardiovascular (CV) hospitalizations and mortality following AF ablation. A multivariate analysis was performed.

Results

The mean age was 61±10 years old, 32.5% were female and 72.2% had persistent AF. Many study patients had modifiable RF, ranging from 4.7% with excessive alcohol use to 64.0% experiencing delayed AF ablation. The mean time from AF diagnosis to ablation was 4.7 years. During a mean follow-up of 1.6 years after ablation, 467 (64.5%) patients met the primary outcome. Independent RF for the primary outcome were an increase/fluctuation in BMI >5% (adjusted hazard ratio [AHR] 1.31, 95% confidence interval [CI] 1.07–1.60; P=0.008), diabetes with HbA1c >6.5% (AHR 1.50, 95% CI 1.09–2.03; P=0.014) and hyperlipidemia without statin therapy (AHR 1.30, 95% CI 1.08–1.57; P=0.005). Delayed AF ablation over 1.5 years did not alter the outcome, Figure 1.

Conclusion

Substantial portions of patients undergoing AF ablation have potentially modifiable RF. Increased or fluctuating BMI, diabetes with HbA1c >6.5%, and hyperlipidemia not treated with statin therapy portend an increased risk of recurrent atrial arrhythmia, CV hospitalizations and mortality. These findings underscore an importance pursuing RF management in patients with AF to reduce adverse outcomes after ablation.

Funding Acknowledgement

Type of funding sources: Private grant(s) and/or Sponsorship. Main funding source(s): The Jensen Family Research Sponsorship at the University of Nebraska Medical Center
Dronedarone as early rhythm control: post-hoc analysis of the ATHENA trial using EAST-AFNET4 criteria
Authors: Kirchhof P , Camm A J , Crijns H J G M , Piccini J P , Torp-Pedersen C , McKindley D , Stewart J , Wieloch M , Hohnloser S H
Published: October 2022

Introduction

The EAST-AFNET4 study found that early, systematic rhythm control reduced cardiovascular (CV) outcomes in patients with early atrial fibrillation/atrial flutter (AF) of ≤12 months compared to guideline-recommended usual care.

Purpose

This post-hoc analysis aimed to assess whether antiarrhythmic drug therapy alone (i.e. dronedarone 400 mg BID) improved CV outcomes compared to placebo in patients with early AF in the ATHENA trial (NCT00174785; Ref 2) applying the EAST-AFNET4 criteria.

Methods

All patients in the randomised, placebo-controlled ATHENA trial with ≥2 CV conditions as defined in the EAST-AFNET 4 inclusion criteria and known AF duration at baseline were identified. Patients were split into early AF (≤12 months duration) and late AF (>12 months duration) subgroups. Outcomes were collected over a mean follow-up of 21 months and included a composite of CV death, stroke, or hospitalisation with worsening of heart failure or acute coronary syndrome; nights spent in hospital per year; and a safety composite endpoint comprising death, stroke, or pre-specified serious adverse events. All analyses were conducted in the intention-to-treat population.

Results

Dronedarone treatment was associated with significantly (p=0.014) fewer CV events vs placebo in patients with early AF (Fig 1). There was no interaction with AF duration (p=0.64). Patients on dronedarone spent numerically fewer nights in hospital vs placebo in early (13.4 vs 14.0) and late AF (13.9 vs 16.3), with no treatment interaction between subgroups (p=NS). Dronedarone was associated with more sinus rhythm (SR) at 12 months vs placebo (early AF: 79.9% vs 70.3%; late AF: 60.6% vs 54.0%), and similar rates of SR at 24 months (early AF: 65.8% vs 65.7%; late AF: 54.7% vs 54.1%). For the safety composite endpoint, estimated events/patients were as follows for the early AF group (dronedarone: 153/135; placebo: 182/165) and the late AF group (dronedarone: 86/81; placebo: 95/89).

Conclusions

The clinical benefit of early rhythm control found in the EAST-AFNET4 trial can be replicated in this analysis of patients with early AF treated in the ATHENA trial comparing dronedarone to placebo. These data support the use of dronedarone as part of early rhythm control.

Funding Acknowledgement

Type of funding sources: Private company. Main funding source(s): Sanofi
Amiodarone and lung toxicity in a real-life contemporary population
Authors: Tsaban G , Gordon M , Omari Y , Kezerle L , Alnsasra H , Buturlin K , Bareza S , Wagshal A , Konnstantino Y , Novack V , Haim M
Published: October 2022

Background

Amiodarone-induced lung toxicity (ALT) is severe and potentially fatal. Most data on ALT are derived from previous decades when amiodarone was administrated chronically in higher doses, while currently, low-dose amiodarone 200 mg is routinely used. Whether low-dose amiodarone treatment is associated with ALT remains untested.

Methods

This is a retrospective study among patients from the Southern district of Clalit Health Services (CHS) in Israel between 1st January 1999 and 1st July 2021. The study population comprised solely of patients with atrial fibrillation since this is the most prevalent condition for prescribing amiodarone. Patients treated with amiodarone were matched in a 1:1 manner with controls not exposed to amiodarone based on age, sex, living area, and atrial fibrillation diagnosis duration. To avoid immortal time bias, follow-up times of the matched controls were left adjudicated to truncate the amiodarone-free period of their matched cases. Patients with prior interstitial lung disease (ILD) were excluded. The primary outcome was the incidence of any ILD. We performed survival analyses using multivariable Cox regression controlling for potential confounders.

Results

During the study period, 7,048 patients who initiated amiodarone treatment were identified, of whom 6,449 were matched with controls. The mean age was 71.5 years, and 46.4% were women among the matched population. The amiodarone-treatment group had higher rates of smoking (30.3% vs. 26.8%, p<0.001), rheumatic disease (4.5% vs. 3.5%, p=0.003), background myocardial infarction (31.6% vs. 19.6%), renal failure (17.2% vs. 10.8%) and congestive heart failure (33.8% vs. 20.7%; p<0.05 for all). During the study, with a mean follow-up time of 5.6 years, ILD occurred in 357 (5.5%) patients in the amiodarone group and 289 (4.5%) patients in the control group [adjusted hazard ratio: 1.09 (confidence interval 95%: 0.91, 1.3), p=0.4].

Conclusion

In a large contemporary real-life population, the incidence of ILD during 5.6 years was relatively low, and treatment with low-dose amiodarone was not associated with an increased risk of ILD. These results, if confirmed by other cohorts, may call for a change in the surveillance policy of patients treated with amiodarone

Funding Acknowledgement

Type of funding sources: None.
Amiodarone therapy and risk of primary lung cancer; insights from a real-life contemporary population study
Authors: Tsaban G , Gordon M , Omari Y , Kezerle L , Alnsasra H , Buturlin K , Bareza S , Wagshal A , Novack V , Konnstantino Y , Haim M
Published: October 2022

Background

Amiodarone is the most effective antiarrhythmic therapy to maintain sinus rhythm in atrial fibrillation (AF) patients. There is a controversy regarding the association of amiodarone therapy with an increased risk of lung cancer. We aimed to assess the relationship between amiodarone treatment and primary lung cancer (PLC) incidence in a contemporary population of AF patients.

Methods

This is a retrospective study among patients from the Southern district of Clalit Health Services in Israel between 1st January 1999 and 1st July 2021. The study population comprised solely of patients with atrial fibrillation since this is the most prevalent condition for prescribing amiodarone. Patients treated with amiodarone were matched in a 1:1 manner with controls not exposed to amiodarone based on age, sex, living area, and atrial fibrillation diagnosis duration. To avoid immortal time bias, follow-up times of the matched controls were left adjudicated to truncate the amiodarone-free period of their matched cases. Patients with prior PLC were excluded. The primary outcome was the incidence of any PLC. We performed survival analyses using multivariable Cox regression controlling for potential confounders.

Results

During the study period, 7,048 patients who initiated amiodarone treatment were identified, of whom 6,449 were matched with controls. The mean age was 71.5 years, and 46.4% were women among the matched population. The amiodarone-treatment group had higher rates of smoking (30.3% vs. 26.8%), prior non-lung-related malignancy (14.9% vs. 13.5%), rheumatic disease (4.5% vs. 3.5%), diabetes (38.3% vs. 32.6%), history of myocardial infarction (316% vs. 19.6%), renal failure (17.2% vs. 10.8%) and congestive heart failure (33.8% vs. 20.7%); p<0.05 for all. During the study, with a mean follow-up time of 5.7 years, PLC occurred in 94 (1.5%) patients in the amiodarone group and 79 (1.2%) patients in the control group [adjusted-hazard-ratio (aHR) 1.10 (confidence-interval 95% (CI95%, 0.78,1.55), p=0.6]. Factors independently associated with increased PLC risk were smoking [aHR 4.25 CI95% (3.01,5.99), p<0.001], non-lung-related malignancy [aHR 1.56, CI95% (1.00,2.42), p=0.050], and peripheral vascular disease [aHR 1.77, CI95% (1.16,2.71), p=0.008]

Conclusion

Chronic amiodarone treatment is not associated with increased risk for PLC. Smoking and prior non-lung-related malignancy and peripheral vascular disease were independently associated with increased PLC risk, suggesting that such patients should undergo closer surveillance for early detection of PLC.

Funding Acknowledgement

Type of funding sources: None.
Predictors of successful cardioversion of recent-onset atrial fibrillation to sinus rhythm with orally inhaled flecainide
Authors: Ruskin J , Dufton C , Maupas J , Crijns H , Elvan A , De Jong J , Oosterhof T , Tuininga Y , Badings E , Aksoy I , Nuyens D , Van Dijk V , Camm A J , Kowey P , Belardinelli L
Published: October 2022

Background

Height, weight, and body mass index (BMI) are well established risk factors for atrial fibrillation (AF) but whether they are also predictors of successful pharmacological cardioversion of AF is unknown. Data from the open-label INSTANT study of flecainide acetate oral inhalation solution (FlecIH) for acute cardioversion of recent-onset symptomatic AF were examined to determine if these anthropometric measures are predictors of successful cardioversion of AF to sinus rhythm (SR) with FlecIH.

Methods

Logistic regression was performed on a broad array of patient and disease characteristics to identify predictors of cardioversion success at 90 minutes post-dose, and potential interactions were examined by boundary restriction analysis. Data are presented for patients receiving 120 mg FlecIH.

Results

Data from 81 patients (32.1% female) with a mean age of 59.8 years (range: 26.0, 84.0) were included in the analysis. This cohort had a mean weight of 87 kg (range: 57, 150), a mean height of 180 cm (range: 156, 199), and a mean BMI of 26.8 kg/m2 (range: 17.2, 37.9). A logistic regression model identified height, weight, and BMI as significant predictors of cardioversion success (p<0.01) and a boundary restriction analysis revealed a negative correlation between BMI and conversion rate across the entire dataset (see Figure 1). Clinically significant conversion rates were observed for patients with BMI values that were considered normal (BMI <25 kg/m2 = 53%; 95% CI: 36, 70), overweight (BMI ≥25 and <30 kg/m2 = 47%; 95% CI: 29, 64), and obese (BMI ≥30 and <35 kg/m2 = 43%; 95% CI: 17, 69); however, none of the severely obese patients (BMI ≥35 mg/m2) had their AF successfully converted to sinus rhythm (see Figure 2).

Conclusions

Successful cardioversion of recent onset AF with 120 mg FlecIH was observed in normal, overweight, and obese patients with BMI values <35 kg/m2; however, conversion rate decreases with increasing BMI. Further evaluation of FlecIH dosing in severely obese patients is warranted.

Funding Acknowledgement

Type of funding sources: Private company. Main funding source(s): InCarda Therapeutics
Feasibility of simultaneous multichannel magnetocardiographic mapping, multiple monophasic action potential recording and laser photocoagulation of isolated and perfused rabbit ventricular myocardium
Authors: Brisinda D , Fenici P , Fenici R
Published: October 2022

Background

Multichannel magnetocardiographic mapping (MCG) has been validated as an accurate non-invasive method for 3D localization of arrhythmogenic substrates suitable for ablation treatment and of intracardiac electrophysiology catheters (1,2). High resolution (HR) MCG-guided multiple simultaneous monophasic action potential (multi-MAP) recording and pacing with a single patented amagnetic catheter (AC) detects local arrhythmogenic mechanisms (3). Laser photocoagulation (LP) providing more controlled and homogeneous myocardial lesions (4), may be an alternative to radiofrequency (RF) ablation, without unwanted electromagnetic noise effect during real-time MCG.

Purpose

This study aimed to experimentally test the feasibility of simultaneous multi-MAP recording and LP guided by real-time MCG.

Methods

An unshielded 36 channels SQUID system (sensitivity of 30 fT/Hz1/2, at 1 Hz) (CMI, USA) was used to study Langendorff-perfused isolated rabbit heart with MCG (Figure 1A). Four epicardial MAPs were simultaneously recorded (inter MAP distance: 1 mm) with a single multi-MAP AC (bandpass: DC-500 Hz; sampling frequency: 2 kHz) (GE-Prucka Cardiolab). LP was performed with a NdYAG laser (Dornier Medilas 5100) and a catheter system for safe myocardium LP (5). The study was carried out according to NIH guidelines for animal care and use.

Results

MCG imaging of rabbit ventricular magnetic field distribution and inverse source localization with the magnetic dipole model are shown in Figure 1B. The difference in morphology of local HR ventricular multi-MAP signals was compatible with myocardial anisotropy (Figure 1C). With appropriate cooling of the optic fiber-tissue interface, no epicardial damage was induced by LP, whereas deeper well defined intramural myocardial lesions were appreciable, of different size as a function of the energy delivered (Figure 1D). Multi-MAP recording was not significantly disturbed by LP. Keeping the Medilas unit at least 5 meters away from the MCG sensors, no electromagnetic artifacts were observed during MCG.

Conclusion

MCG, single catheter multi-MAP recording and well-defined LP lesions of ventricular myocardium were simultaneously feasible on Langendorff-perfused isolated rabbit heart, without major electromagnetic interferences, in an unshielded catheterization laboratory. With appropriate technological developments, safe MCG-guided single-catheter laser ablation of focal arrhythmogenic substrates is foreseen as a possible minimally invasive alternative to current interventional approaches.

Funding Acknowledgement

Type of funding sources: None.
Predictors of the presence of typical atrial flutter in patients undergoing atrial fibrillation ablation
Authors: Ulus T , Yilmaz A S , Al A , Sener E , Durmaz F E
Published: October 2022

Background

Typical cavotricuspid isthmus (CTI) dependent atrial flutter (Afl) may develop spontaneously in patients undergoing atrial fibrillation (AF) ablation and it is also responsible for a significant portion of recurrences after AF ablation. In this situation, the second ablation for typical Afl is frequently needed. If the predictors of typical Afl can be known in such patients, CTI ablation for typical Afl can also be performed in the same session as AF ablation. Thus, the risks and increased costs of the second ablation procedure can be avoided. There is insufficient data related to the predictors of typical Afl in patients undergoing AF ablation.

Purpose

In this study, we aimed to investigate the predictors of typical Afl in patients undergoing catheter ablation for AF.

Methods

In this retrospective study, we consecutively enrolled 135 patients with AF undergoing index catheter ablation. Patients who did not come regular follow-up after ablation were excluded. Thus, 131 patients were included. The patients were divided two groups according to spontaneous typical Afl development before or after AF ablation. They were compared in terms of baseline characteristics and procedural features.

Results

The mean age of the patients was 58 (48–62), 65 of them (49.6%) were male, typical Afl was observed in 20 patients (15.2%). The frequency of male gender was higher (80.0% vs 44.1%, p=0.003), the left ventricular (LV) ejection fraction was lower (56.2±10.9% vs 60.7±6.7%, p=0.015), LV end-diastolic diameter was higher [50.0 (48.2–53.0) vs 47.0 (44.0–49.0), p<0.001), the left atrium diameter was higher (41.4±4.5 vs 38.4±4.5, p=0.008), and the right atrium (RA) diameter was higher (41.6±3.5 vs 36.8±3.7, p<0.001) in patients with typical Afl than in those without it (Figure 1a). Laboratory measurements, drug use, and procedural characteristics were similar between groups. A logistic regression analysis demonstrated that male gender [OR: 4.5, 95% CI: 1.01–20.03, p=0.048) and the RA diameter [OR: 1.57, 95% CI: 1.22–2.02, p<0.001] were independent predictors of the presence of typical Afl (Figure 1b). A Receiver Operating Characteristic curve showed that optimal cut-off value of the RA diameter to predict the presence of typical atrial flutter was 40.5 mm (AUC: 0.843, sensitivity %80, specificity %85, p<0.001) (Figure 2).

Conclusion

A RA diameter greater than 40.5 mm may predict the presence of spontaneous typical Afl in patients undergoing catheter ablation for AF. This information can help to identify patients who would benefit from CTI ablation in the same session as AF ablation.

Funding Acknowledgement

Type of funding sources: None.